The Biotech BU offers alternative research & development pathways for new innovative therapies using partnerships

Oncodesign, via its Biotech BU, is pursuing innovative approaches to novel and next generation kinase inhibitors, diagnostic molecules PET-tracers for precision medicine and systemic targeted radiotherapies. These approaches are based on Oncodesign’s proprietary platforms: Nanocyclix® and MRT (Molecular RadioTherapy)

nanocyclix

Nanocyclix®, our innovative technology to generate new kinase inhibitors

Nanocyclix® is our medicinal chemistry technology that uses small macrocyclic kinase inhibitor molecules to develop new therapies and PET radiotracers. The platform creates optimal value thanks to our chemical biology approach of “Probe-based Drug Discovery”, in which new and untreatable kinases are targeted. Nanocyclix® is a set of potent and selective inhibitors for phenotype-based approaches in translational models that are ideal due to their intrinsic cellular activity. Incorporating a radiolabel into these molecules generates new PET tracers for the purpose of precision medicine. The development of Nanocyclix® molecules is greatly improved by Artificial Intelligence which capitalizes on the huge dataset that we have generated since the creation of the platform.

Our internal portfolio

Highly innovative programs covering first-in-class and best-in-class opportunities in several therapeutic areas!

EGFRi

Oncology PET-tracer

RIPK2i

Immunology

LRRK2i

Parkinson's Disease

MNK1/2i

Oncology

Partnership opportunities to find the treatments of tomorrow together

We are committed to forming partnerships at every step of the drug discovery process, using these technologies to support your treatment programs and offer alternative development pathways so we can bring new therapies to the patients who truly need it. We have extensive experience forming alliances with leading academic teams, foundations, and biotechnology and pharmaceutical companies across the world. Do you want access to cutting-edge technology and expertise in kinase inhibition, precision medicine, PET tracers and systemic radiotherapy?

opportunites
A small molecule or antibody with a radioactive isotope bind selectively to a cancer cell

Expand our portfolio in the field of Molecular RadioTheray

Through our Pharmimage® platform, we have built state-of-the-art infrastructure and generated in depth knowledge for the creation of new molecular radiotherapeutics based on innovative vector, linker and isotope chelating technology. MRTs are a rapidly growing field in oncology, creating tremendous opportunities for cancer patients. These agents target specific receptors on the surface of tumor cells, which are killed in a selective manier through irradiation from the radio-isotope that is part of each MRT Molecule.

The latest Biotech resources

Biotech
29/06/2022

In vitro pharmacological profile of Compound A

Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent and selective LRRK2 inhibitor.

Biotech
29/06/2022

In vivo PK/PD profile of Compound A

Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor.